FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular, the invention relates to a monoclonal antibody or an antigen-binding fragment thereof, which specifically binds to a rusticyanin protein, nucleic acids coding them, as well as to the use of antibodies as anticancer agents and pharmaceutical compositions with anticancer activity. Said antibodies or antigen-binding fragments of antibodies are characterized by high antiproliferative action, high efficiency in inhibiting tumour growth, as well as ability to reduce viability of tumour cells.
EFFECT: invention widens the range of anticancer agents, including for treating malignant growths.
17 cl, 5 dwg, 7 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROPERDIN ANTIBODIES AND PRODUCTION THEREOF | 2021 |
|
RU2830308C1 |
| BISPECIFIC ANTIBODIES AND THEIR APPLICATIONS | 2022 |
|
RU2821577C2 |
| MONOCLONAL ANTIBODY IC2 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817697C1 |
| IDE ANTIBODIES AND USE THEREOF | 2020 |
|
RU2839026C1 |
| ANTIBODY B7H6 AND ITS USE | 2022 |
|
RU2834783C2 |
| MONOCLONAL ANTIBODIES AGAINST THE RECEPTOR-BINDING DOMAIN OF SARS-COV-2 SPIKE PROTEIN AND THEIR ANTIGEN-BINDING FRAGMENTS ENCODING THEIR NUCLEIC ACIDS, AS WELL AS METHODS OF THEIR USE | 2021 |
|
RU2800649C2 |
| MONOCLONAL ANTIBODY IC1 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817696C1 |
| FUSION PROTEIN OF GPC3 TARGETING ANTIBODY AND INTERFERON α AND USE THEREOF | 2022 |
|
RU2836245C2 |
| BCMA-SPECIFIC CHIMERIC ANTIGEN RECEPTORS CONTAINING IL-6 SIGNALLING BLOCKER | 2023 |
|
RU2828294C1 |
| ANTIBODIES | 2005 |
|
RU2482131C2 |
